233 related articles for article (PubMed ID: 18571471)
1. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
McAlister FA; Eurich DT; Majumdar SR; Johnson JA
Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
[TBL] [Abstract][Full Text] [Related]
2. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
3. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz M; Martínez-Abundis E;
Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
[TBL] [Abstract][Full Text] [Related]
5. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
[TBL] [Abstract][Full Text] [Related]
6. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
7. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
[TBL] [Abstract][Full Text] [Related]
8. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
9. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
10. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
11. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
[TBL] [Abstract][Full Text] [Related]
13. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
14. Mortality risk with sulphonylureas compared to metformin.
Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):885-90. PubMed ID: 24533964
[TBL] [Abstract][Full Text] [Related]
15. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
[TBL] [Abstract][Full Text] [Related]
16. Long term patterns of use after initiation of oral antidiabetic drug therapy.
Lamberts EJ; Nijpels G; Welschen LM; Hugtenburg JG; Dekker JM; Souverein PC; Bouvy ML
Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):351-8. PubMed ID: 21442684
[TBL] [Abstract][Full Text] [Related]
17. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
19. Metformin use in decompensated heart failure.
Boyd A; Nawarskas J
Cardiol Rev; 2008; 16(5):269-72. PubMed ID: 18708828
[TBL] [Abstract][Full Text] [Related]
20. [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].
Nauck MA; Matthaei S
Dtsch Med Wochenschr; 2005 Apr; 130(17):1091-6. PubMed ID: 15841424
[No Abstract] [Full Text] [Related]
[Next] [New Search]
